Simone Seiter
Director/Board Member bei GENSIGHT BIOLOGICS S.A.
Profil
Simone Seiter is the founder of Priothera SAS.
He is currently an Independent Director at Gensight Biologics SA since 2017.
Previously, he worked as a Vice President at IQVIA from 2006 to 2019.
He also held a position as a Senior Partner at Simon-Kucher & Partners, Inc. Dr. Seiter has a graduate and doctorate degree from Ruprecht-Karls-Universität Heidelberg and an MBA from the University of Applied Sciences Fh Rendsburg.
Aktive Positionen von Simone Seiter
| Unternehmen | Position | Beginn |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Director/Board Member | 19.04.2017 |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Founder | - |
Ehemalige bekannte Positionen von Simone Seiter
| Unternehmen | Position | Ende |
|---|---|---|
| IQVIA | Corporate Officer/Principal | 01.01.2019 |
| Simon-Kucher & Partners, Inc. | Corporate Officer/Principal | - |
Ausbildung von Simone Seiter
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| University of Applied Sciences Fh Rendsburg | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| IQVIA | |
| Simon-Kucher & Partners, Inc. | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Health Technology |
